Nakasone H, Tanaka Y, Yamazaki R, Terasako K, Sato M, Sakamoto K, Yamasaki R, Wada H, Ishihara Y, Kawamura K, Machishima T, Ashizawa M, Kimura S-I, Kikuchi M, Tanihara A, Kanda J, Kako S, Nishida J, Kanda Y
Division of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
Bone Marrow Transplant. 2014 Jan;49(1):87-94. doi: 10.1038/bmt.2013.122. Epub 2013 Aug 12.
Cellular immunity is important for the control of CMV infection after allogeneic hematopoietic cell transplantation (Allo-HCT). However, the actual in vivo dynamics of CMV-specific cytotoxic T cell (CMV-CTL) clones are still unclear. We conducted clone monitoring of tetramer(+) CMV-CTLs in HLA-A2402-positive donor-patient pairs, using a direct single-cell analysis that enabled the simultaneous identification and quantification of CTL clones. Clone dynamics were assessed in three cases with or without CMV reactivation. In Case-1 without CMV reactivation, despite the long-term use of systemic steroid, dominant clones of Donor-1 persisted and remained dominant. The CMV-CTLs at 1 year after Allo-HCT included a high proportion of CD45RA(+)CCR7(-) effector and CD27(-)CD57(+)mature T cells. On the other hand, in Cases-2 and -3 with CMV reactivation, novel clones appeared and became dominant during the follow-up. Their CMV-CTLs included more CD27(+) immature T cells at 1 year after Allo-HCT. With regard to clonotypes, HLA-A2402-restricted CMV-CTLs tended to select BV7 and BJ1-1 genes for complementarity-determining region 3 (CDR3) of T-cell receptor (TCR)-β. Specific amino-acid sequences of CDR3 of TCR-β were found in each case. Patterns of clone reconstitution and phenotype would be different according to CMV reactivation. In vivo clone monitoring of CMV-CTLs could provide insight into the mechanism of immunological reconstitution following Allo-HCT.
细胞免疫对于异基因造血细胞移植(Allo-HCT)后巨细胞病毒(CMV)感染的控制至关重要。然而,CMV特异性细胞毒性T细胞(CMV-CTL)克隆在体内的实际动态仍不清楚。我们使用直接单细胞分析方法,对HLA-A2402阳性供体-患者对中的四聚体(+)CMV-CTL进行克隆监测,该方法能够同时鉴定和定量CTL克隆。在3例有或无CMV再激活的病例中评估克隆动态。在病例1中,无CMV再激活,尽管长期使用全身性类固醇,但供体1的优势克隆持续存在并保持优势。Allo-HCT后1年的CMV-CTL包括高比例的CD45RA(+)CCR7(-)效应细胞和CD27(-)CD57(+)成熟T细胞。另一方面,在有CMV再激活的病例2和病例3中,新克隆出现并在随访期间成为优势克隆。它们的CMV-CTL在Allo-HCT后1年包括更多的CD27(+)未成熟T细胞。关于克隆型,HLA-A2402限制性CMV-CTL倾向于为T细胞受体(TCR)-β的互补决定区3(CDR3)选择BV7和BJ1-1基因。在每个病例中都发现了TCR-β的CDR3的特定氨基酸序列。根据CMV再激活情况,克隆重建和表型模式会有所不同。对CMV-CTL进行体内克隆监测可以深入了解Allo-HCT后免疫重建的机制。